Ekso Bionics Holdings, Inc. (EKSO)

Ekso Bionics Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	17.91	18.28	12.91	11.25	8.88	13.92
Revenue Growth (YoY)	23.82%	41.57%	14.81%	26.62%	-36.18%	22.81%
Cost of Revenue	8.88	9.2	6.7	4.5	3.81	7.15
Gross Profit	9.03	9.08	6.21	6.75	5.07	6.76
Selling, General & Admin	17.94	19.17	18.14	18.03	15.45	18.81
Research & Development	5.01	5.03	3.63	2.55	2.47	4.6
Other Operating Expenses	0	0	0	0	0.43	0
Operating Expenses	22.95	24.19	21.77	20.58	18.36	23.4
Operating Income	-13.92	-15.11	-15.56	-13.83	-13.29	-16.64
Interest Expense / Income	0.25	0.3	0.16	0.11	0.14	0.38
Other Expense / Income	0.07	-0.22	-0.63	-4.18	2.4	-4.89
Pretax Income	-14.24	-15.2	-15.08	-9.76	-15.83	-12.13
Net Income	-14.24	-15.2	-15.08	-9.76	-15.83	-12.13
Shares Outstanding (Basic)	17	14	13	12	7	5
Shares Outstanding (Diluted)	17	14	13	12	7	5
Shares Change	31.01%	6.98%	5.65%	71.26%	49.44%	17.44%
EPS (Basic)	-0.97	-1.10	-1.16	-0.80	-2.21	-2.53
EPS (Diluted)	-0.97	-1.10	-1.16	-0.88	-2.21	-2.53
Free Cash Flow	-11.43	-12.21	-14.86	-11.22	-8.76	-15.83
Free Cash Flow Per Share	-0.66	-0.88	-1.15	-0.92	-1.22	-3.30
Gross Margin	50.41%	49.67%	48.13%	60.01%	57.08%	48.60%
Operating Margin	-77.71%	-82.67%	-120.48%	-122.96%	-149.64%	-119.56%
Profit Margin	-79.48%	-83.14%	-116.79%	-86.82%	-178.17%	-87.17%
Free Cash Flow Margin	-63.80%	-66.80%	-115.11%	-99.72%	-98.57%	-113.76%
EBITDA	-12.3	-13.2	-14.04	-8.63	-15.07	-11.06
EBITDA Margin	-68.67%	-72.20%	-108.71%	-76.72%	-169.62%	-79.46%
Depreciation & Amortization	1.69	1.7	0.89	1.02	0.62	0.69
EBIT	-13.99	-14.9	-14.92	-9.65	-15.69	-11.75
EBIT Margin	-78.10%	-81.49%	-115.58%	-85.82%	-176.60%	-84.41%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).